In this framework, systemic treatment with Hu5F9-G4, which disrupts the interaction between CD47 and SIRPα, resulted in shrinkage of primary tumors and leptomeningeal metastasis in mouse models with implanted patient-derived group 3 medulloblastoma xenografts and mouse cell lines of this subgroup. The gene discussed is CD47; the disease is medulloblastoma.